| Coordination for Multi-Cancer Detection Tests |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCI |
Coordination of development of multi-cancer detection (MDC) tests for clinical research use |
| Council of Federal Executive Secretariats |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, OIG |
OD/IMOD/ES |
Representatives from Executive Secretariats across government meet monthly for information exchange, knowledge sharing, and to receive updates from the White House Office of Presidential Correspondence Office. |
| Country Work in Cancer Research and Cancer Control Planning Strengthening: Kenya |
Resource Development |
CDC |
FIC, NCI, NIAID |
Kenya has an estimated population of approximately 53 million (World Bank). Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus, and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in the country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M, and USAID invested $700 million in Kenya in FY2011. At least six NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH) partnership, along with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012. |
| COVID antibody testing |
Research Initiative |
ASPR |
NIAID |
Testing of candidate therapeutic antibodies for neutralization against SARS-CoV-2 variants |
| Covid Serology Research and Results Tracker (SeroHub) |
Resource Development |
CDC |
NCI, NIAID |
The Covid-19 Serology Research Tracking System and Dasboard serves as a research resource to the NCI/NIAID/CDC and to the broader research community to monitor seroprevalence. Project is slated to end in August 2024. DCEG contact is Dr. Stephen Chanock. |
| COVID-19 and Influenza Scenario Modeling Hubs |
Research Initiative |
CDC |
FIC |
Collaboration between NIH, CDC and academia for disease projections. From weather to infectious diseases, it has been shown that synergizing results from multiple models gives more reliable projections than any one model alone. The COVID-19 Scenario Modeling Hub is a collaborative effort between multiple government agencies and academic institutions to harmonize COVID-19 projections in the United States and facilitate planning and decision making at a 3-12 month time scale. Since December 2020, the COVID19 scenario modeling hub has released 12 rounds of projections on issues as varied as the impact of the vaccination program, non-pharmaceutical interventions, waning immunity, and new variants on the trajectory of cases, hospitalizations and deaths across the US. The most recent set of projections addresses the impact of Omicron. In each round of projections, a set of 4 scenarios are identified to allow alignment of model projections for collective insights. Scenarios are designed in consultation with academic modeling teams, NIH and the CDC. Between 6 and 10 models have contributed to each round. All projections are made publicly available via the COVID-19 scenario modeling hub github and website. After each round, a report summarizing key results is shared with decision-makers and public health stakeholders. There has been substantial media coverage on this effort and results have been used by CDC/ACIP to guide COVID19 vaccine recommendations. The hub expanded in 2022 to generate influenza projections. This study builds on long-standing efforts led by the Fogarty International Center's in-house research division to develop computational approaches to mitigate pandemic risk and foster collaborative network in disease modeling. This effort extends a prior collaboration titled the Multinational Influenza Seasonal Mortality Study (MISMS) to assess the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses. Multinational and bilateral collaborations developed through MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. These research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications. |
| COVID-19 Scientific Interest Group |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCCIH, NCI, NEI, NHGRI, NHLBI, NIAID, NIAMS, NIEHS, NIMHD, NINDS |
Scientific interest group discussing science, clinical, epidemiology, and social issues around SARS-CoV-2 and COVID-19. Includes members from FDA. Organizes seminars, workshops, websites, and originally cataloging research and reagents at NIH and FDA intramural programs. |
| COVID-19 Therapeutics Resistance Task Team (for SIG) |
Committee, Work group, Advisory group, or Task Force |
ASPR, CDC, FDA |
NIAID |
To share updates on the wide range of COVID therapeutics efforts that are progressing across the agencies, with a focus on emerging variants and possible drug resistance |
| COVID-RADx-UP Working Group |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCATS, NEI, NIBIB |
The overarching goal of the RADx-UP initiative is to understand the factors associated with disparities in COVID-19 morbidity and mortality and to lay the foundation to reduce disparities for those underserved and vulnerable populations who are disproportionately affected by, have the highest infection rates of, and/or are most at risk for complications or poor outcomes from the COVID-19 pandemic. |
| CRIMM Biorepository PCT |
Committee, Work group, Advisory group, or Task Force |
BARDA |
NIAID |
The focus of the working group is to advise on the CRIMM Biorepository. |